Supplementary Figure 7: PGE2-induced suppression of nigericin-triggered NLRP3 inflammasomes is mediated by PKA, but particulate NLRP3 agonists are not.
From: NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations
(a-f) BMDMs primed for 3.5 h with LPS. (a) Rp-cAMP was added 5 min before or (b) PKI was added 30 min before treatment with EP2 agonist ONO-AE1-259-01 (50 nM) for 5 min followed by nigericin (5 μM for 30 min). (c) Rp-cAMP was added 5 min before or (d) PKI was added 30 min before treatment with EP4 agonist ONO-AE1-329 (500 nM) for 5 min followed by nigericin (5 μM for 30 min). (e) PKI was added 30 min before or (f) Rp-cAMP was added 5 min before (e,f) PGE2 (500 nM) treatment for 5 min followed by addition of MSU (125 μg/ml for 4h) or silica (250 μg/ml for 5h). (a,c,e,f) Immunoblot analysis of culture supernatants (SN) and lysates (LYS). (a-f) Total IL-1β release in cell supernatants analyzed by ELISA. *P < 0.005 (unpaired two-tailed t test). (a-f) Data are from one experiment representative of three separate experiments with similar results, (a-f) BMDM were derived from 2 mice per experiment mixed together, (a-f) three replicates, each replicate is one well + s.e.m.
